



Press Release

**Termination of Global Development of Therapeutic Agent
for Chronic Kidney Disease**

Tokyo, Japan, October 30, 2013 – Kureha announced today that Kureha and Mitsubishi Tanabe Pharma Corporation mutually agreed to terminate the development of Kremezin, a therapeutic agent for chronic kidney disease, in Europe and the Americas. The two companies have been discussing over the direction of the development after completion of Global Phase III (EPPIC) Studies for Kremezin, as announced on October 10, 2012.

The decision to terminate the above-mentioned development does not impact Kureha's performance forecast for fiscal 2013, ending March 30, 2014, released on August 2, 2013.

For further information, please contact,

Kureha Corporation

Public & Investor Relations Department Tel. 03-3249-4651